mTOR — research review 2

...and this is where we see the rubber meet the road in longevity science: the difference between promising lab results and what actually works in humans.

Exactly. Take mTOR, for instance. It's a growth signal pathway, well-known for suppressing autophagy when nutrients are plentiful. Autophagy, of course, being that crucial cellular cleanup process.

So, in a petri dish or a mouse model, inhibiting mTOR looks fantastic for boosting autophagy and potentially extending lifespan. There's even a molecule, AMPK, that naturally inhibits mTOR, essentially releasing that brake on cellular recycling.

Right. The theory is solid, supported by extensive preclinical work. But when we look for direct human evidence of, say, an mTOR inhibitor directly translating into extended human lifespan or even a significant reduction in age-related disease, the picture gets much murkier.

We have studies, like one in Science from 2009, showing mTOR inhibition extending lifespan in mice. But that leap to humans isn't straightforward. We still lack large-scale, long-term human clinical trials definitively demonstrating that manipulating mTOR in healthy people translates into significantly longer, healthier lives.

And this is crucial. Many interventions that look good in early stages don't pan out in rigorous human trials, or the effects are far smaller than anticipated. We just don't have the robust human data yet to say, "Yes, X intervention targeting mTOR will definitely add years to your life." We're still very much in the exploratory phase regarding human application.